Premium
Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5‐fluorouracil resistance in metastatic colorectal cancer patients
Author(s) -
Abdallah Emne Ali,
Fanelli Marcello Ferretti,
Buim Marcilei Eliza Cavicchioli,
Machado Netto Marcelo Calil,
Gasparini Junior José Luiz,
Souza e Silva Virgílio,
Dettino Aldo Lourenço Abbade,
Mingues Natalia Breve,
Romero Juliana Valim,
Ocea Luciana Menezes Mendonça,
Rocha Bruna Maria Malagoli,
Alves Vanessa Silva,
Araújo Daniel Vilarim,
Chinen Ludmilla Thomé Domingos
Publication year - 2015
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.29495
Subject(s) - thymidylate synthase , colorectal cancer , fluorouracil , circulating tumor cell , medicine , chemotherapy , oncology , cancer , immunocytochemistry , primary tumor , pathology , cancer research , metastasis
Thymidylate synthase (TYMS) is an important enzyme for 5‐fluorouracil (5‐FU) metabolism in metastatic colorectal cancer (mCRC) patients. The search for this enzyme in circulating tumor cells (CTCs) can be a powerful tool to follow‐up cancer patients. mCRC patients were enrolled before the beginning of 5‐FU‐based chemotherapy. The blood was filtered on Isolation by Size of Epithelial Tumor Cells (ISET), and the analysis of TYMS expression in CTCs was made by immunocytochemistry. Additionally, we verified TYMS staining in primary tumors and metastases from the same patients. There were included 54 mCRC patients and 47 of them received 5‐FU‐based chemotherapy. The median CTCs number was 2 per mL. We were not able to analyze immunocytochemistry in 13 samples (9 patients with absence of CTCs and 4 samples due to technical reasons). Therefore, TYMS expression on CTCs was analyzed in 34 samples and was found positive in 9 (26.5%). Six of these patients had tumor progression after treatment with 5‐FU. We found an association between CTC TYMS staining and disease progression (DP), although without statistical significance ( P = 0.07). TYMS staining in primary tumors and metastases tissues did not have any correlation with disease progression ( P = 0.67 and P = 0.42 respectively). Patients who had CTC count above the median (2 CTCs/mL) showed more TYMS expression ( P = 0.02) correlating with worse prognosis. Our results searching for TYMS staining in CTCs, primary tumors and metastases suggest that the analysis of TYMS can be useful tool as a 5‐FU resistance predictor biomarker if analyzed in CTCs from mCRC patients.